In this online, self-learning activity:
Meningococcal disease is a potentially severe bacterial infection caused by Neisseria meningitidis that may lead to serious sequelae and death in some even with appropriate treatment. N. meningitidis is a leading cause of bacterial meningitis and sepsis in the United States. Since the peak of the disease in the late 1990s, the incidence has declined annually and was at historic low rate of 0.11 per 100,000 population (349 cases) in the year 2017. Among the identified bacterial serogroups, B, C, and Y cause the majority of cases in the United States. Sixty percent of cases among patients 0-59 months and 50% of cases among 17-23 years of age are caused by serogroup B. Seventy-three percent of all cases among eleven year old or more are caused by serogroups C, W, or Y.
This activity has been designed for HCPs to review and update vaccination guidelines, raise awareness of gaps in practice, and improve competence and performance related to vaccination of eligible patients.
The following HCPs: primary care physicians, pediatricians, and public health professionals; physician assistants, nurse practitioners, nurses, and pharmacists who practice in family medicine; and any other clinicians with an interest in or who commonly encounter patients eligible for vaccination against meningococcal disease.
Commercial Support Disclosure: This activity is supported by an educational grant from GlaxoSmithKline
Learners may participate in this activity free of charge.
Release Date: September 24, 2019 -- Expiration Date: September 24, 2021
Faculty: Shira Shafir, Ph.D., MPH
Background: review of meningococcal disease
Barriers to optimal care in patients eligible for vaccination
Summary, conclusions, and best practice recap
By the end of the session the participant will be able to:
ACCME Activity #201349112ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Shira C. Shafir, Ph.D., MPH has no relevant conflicts of interest to disclose.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant conflicts of interest to disclose.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Novel antimicrobials and infectious disease practice: Research updates from ID Week 2019
Treating Oncology Patients During COVID-19
The problem with vaccines: Public hesitancy and refusal
Human immunodeficiency virus (HIV): Updates in care for the primary care physician